NSETrading Window26 Jun 2026 · 26 Jun 2026, 05:06 pm

Trading Window

Orchid Pharma Limited · ORCHPHARMA

✦ AI SummaryResults

Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact6/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

ORCHPHARMA_26062026170426_Stx_ltr_windowclosure_sgn.pdf

pdf

Download →
View document text
June 26, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: (i) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended, read with the Code of Conduct to regulate, monitor and report trading by Insiders of Orchid Pharma Limited “the Company”) (ii) SEBI Circular no. SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023 Sub: Intimation of Trading Window Closure for the Quarter-I of Financial Year 2026-27, ending on June 30, 2026 Dear Sir/Madam, With reference to the captioned subject and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (‘PIT Regulations’), as amended, read with the Company’s Code of Conduct to regulate, monitor and report trading by Insiders, it is hereby intimated that Trading Window for trading in Securities of the Company shall remain closed from July 01, 2026 (‘Trading Window Closure commencement date’) till the date on which 48 hours ends (‘Trading Window Closure end date’) after declaration of Unaudited Limited Reviewed Financial Results (Standalone and Consolidated) of the Company for the Quarter-I of Financial Year 2026- 27, ending on June 30, 2026 (‘Trading Window Closure Period’). The date of meeting of the Board of Directors of the Company, inter-alia, to consider and approve the Unaudited Limited Reviewed Financial Results (Standalone and Consolidated) for the Quarter-I of Financial Year 2026-27, ending on June 30, 2026 will be intimated separately in due course. Accordingly, all persons to whom the Company’s Code of Conduct to regulate, monitor and report trading by Insiders is applicable and the persons, to whom the said code is not applicable but are in possession of Unpublished Price Sensitive Information of the Company, are hereby intimated not to trade in the Securities of the Company during the said Trading Window Closure Period. We request you to take the above intimation on records. Thanking You, For Orchid Pharma Limited Kapil Dayya Company Secretary & Compliance Officer Membership No.: F10698 Orchid Pharma Limited Regd. Office: Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Dist.- 603110, Tamil Nadu, India Phone: (91)-44- 2744 4471/72/73 Email: Corporate@orchidpharma.com Website: www.orchidpharma.com CIN: L24222TN1992PLC022994